Mosquito-Borne Infections Testing Market Report 2026

The mosquito-borne infections testing market size has grown strongly in recent years. It will grow from $1.44 billion in 2025 to $1.56 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing prevalence of dengue and malaria outbreaks, limited access to advanced diagnostic infrastructure in developing regions, growing awareness of vector-borne disease burden, expansion of laboratory testing capacity in urban healthcare systems, rising government funding for infectious disease control programs.

The mosquito-borne infections testing market size is expected to see strong growth in the next few years. It will grow to $2.12 billion by 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to climate change driven expansion of mosquito habitats and disease transmission zones, increasing adoption of rapid molecular diagnostic technologies, growth in real time outbreak monitoring and predictive surveillance systems, rising demand for integrated public health data reporting systems, expansion of personalized and precision infectious disease diagnostics. Major trends in the forecast period include rising incidence of mosquito-borne outbreaks driving demand for rapid diagnostic testing, expansion of decentralized and point-of-care testing in rural and remote regions, increasing adoption of multiplex assays for simultaneous detection of multiple vector-borne pathogens, growing government-led surveillance and screening programs for early outbreak detection, rising preference for portable and field-deployable diagnostic kits for faster epidemic response.

The increasing incidence of dengue diseases is expected to propel the growth of the mosquito borne infections testing market going forward. Dengue is a mosquito-borne viral infection caused by the dengue virus and transmitted primarily by Aedes mosquitoes. The incidence of dengue diseases is rising due to warmer temperatures and increased rainfall, which create favorable breeding conditions for Aedes mosquitoes, along with rapid urbanization that increases human exposure to mosquito populations. Mosquito-borne infections testing contributes to early detection and monitoring of dengue infections by identifying the presence of the virus in patients, thereby enabling timely medical intervention and supporting public health measures to control the spread of the disease. For instance, in July 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, Brazil documented that of the 2,376,522 dengue cases recorded up to epidemiological week 26, 1,051,773 (44.2%) were laboratory-confirmed, and 1,249 (0.05%) were classified as severe dengue, reflecting a 13% increase compared to the same period in 2022. Therefore, the increasing incidence of dengue diseases is propelling the growth of the mosquito borne infections testing market.

The increasing international travel and trade is expected to propel the growth of the mosquito borne infections testing market going forward. International travel and trade refer to the movement of people and goods across countries for purposes such as tourism, business, and global commerce. International travel and trade are expanding due to the easing of COVID-19 restrictions, which has facilitated greater global mobility for travelers and strengthened the flow of goods across international borders. International travel and trade contribute to the movement of people and goods between regions, which can introduce mosquito-borne pathogens to new geographic areas, thereby necessitating enhanced monitoring and testing for these infections to prevent potential outbreaks. For instance, in May 2024, according to the National Travel and Tourism Office (NTTO), a US-based federal government agency, total international visitor arrivals of 66.5 million in 2023 increased by 15.7 million from 50.8 million in 2022, highlighting a significant rise in global travel. Therefore, the increasing international travel and trade is propelling the growth of the mosquito borne infections testing market.

Leading companies operating in the mosquito-borne infections testing market are focusing on developing innovative methods such as automated high-throughput immunoassays to deliver faster, more accurate, and scalable detection of mosquito-borne pathogens. Automated high-throughput immunoassays are laboratory tests that automatically detect specific antigens or antibodies in large numbers of samples, helping provide rapid, accurate, and scalable diagnosis of mosquito-borne infections compared to traditional manual tests. For example, in October 2025, F. Hoffmann-La Roche Ltd., a Switzerland-based biotechnology and diagnostics company, received CE mark for its Elecsys Dengue Ag test, an innovative automated immunoassay designed to detect the NS1 antigen of the dengue virus in human serum and plasma. This test operates on Roche’s fully automated cobas e analysers, providing results in just 18 minutes and reliably detecting all four dengue virus serotypes. Key features include high clinical sensitivity and specificity, medium-to-high throughput of 120-300 tests per hour, enhanced traceability, and workflow efficiency, making it particularly useful during dengue outbreaks for rapid patient management and surveillance. The Elecsys Dengue Ag test represents a significant advancement over conventional methods, delivering consistent, fast, and comprehensive diagnostic capabilities across the entire patient journey.

Major companies operating in the mosquito-borne infections testing market are F. Hoffmann-La Roche Ltd, Trinity Biotech plc, Thermo Fisher Scientific Inc., Abbott Laboratories, Laboratory Corporation of America Holdings (LabCorp), Grifols S. A., Hologic Inc., bioMérieux SA, Bio-Rad Laboratories Inc., QIAGEN N. V., DiaSorin S. p. A., Euroimmun Medizinische Diagnostika AG, SD Biosensor Inc., Promega Corporation, Mayo Clinic Laboratories, Meridian Bioscience Inc., R-Biopharm AG, Boditech Med Inc., NanoEntek Inc., Entomogen Inc., J. Mitra and Co. Pvt. Ltd., Today's Clinical Lab Pvt. Ltd., Co-Dx Inc.

Asia-Pacific was the largest region in the mosquito-borne infections testing market in 2025. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the mosquito-borne infections testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mosquito-borne infections testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mosquito-borne infections testing market consists of revenues earned by entities by providing services such as vector surveillance and mosquito population monitoring, laboratory research and outbreak management, preventive screening, outbreak tracking and reporting, and public health consultation and planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The mosquito-borne infections testing market also includes sales of serological assay kits, rapid test kits, reagents and consumables, and laboratory equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.